Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).

被引：0

作者：

Lee, Kyoungmin

Lee, Kyung-Hun

Kim, Dong-Wan

Yoon, Jeesun

Choi, Wonyoung

Lee, Youngjoo

Choi, Yoon Ji

Lee, Soohyeon

Kim, Ju Won

Ryu, Hyewon

Koo, Dong-Hoe

Lee, Yun-Gyoo

Jeung, Hei-Cheul

Lee, Min-Young

Lee, Namsu

Kang, Myoung Joo

Lee, Ji Eun

Hong, Sook Hee

Kang, Eun Joo

Park, Inhae

机构：

[1] Korea Univ, Div Hematol Oncol, Dept Internal Med, Guro Hosp,Coll Med, Seoul, South Korea

[2] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Coll Med,Canc Res Inst, Seoul, South Korea

[3] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[4] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Seoul, South Korea

[5] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea

[6] Natl Canc Ctr, Div Hematol & Oncol, Dept Internal Med, Goyang, South Korea

[7] Natl Canc Ctr, Div Hematol & Oncol, Dept Internal Med, Goyang Si, South Korea

[8] Korea Univ, Div Hematol Oncol, Dept Internal Med, Anam Hosp,Coll Med, Seoul, South Korea

[9] Korea Univ, Anam Hosp, Coll Med, Seoul, South Korea

[10] Korea Univ, Anam Hosp, Seoul, South Korea

[11] Chungnam Natl Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Coll Med, Daejeon, South Korea

[12] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Kangbuk Samsung Hosp,Sch Med, Seoul, South Korea

[13] Yonsei Univ, Dept Med Oncol, Gangnam Severance Hosp, Coll Med, Seoul, South Korea

[14] Soonchunhyang Univ, Div Hematol & Oncol, Dept Internal Med, Seoul Hosp, Seoul, South Korea

[15] Inje Univ, Haeundae Paik Hosp, Div Hematol Oncol, Dept Internal Med, Busan, South Korea

[16] Catholic Univ Korea, Div Med Oncol, Dept Internal Med, Seoul St Marys Hosp,Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3134

引用

页数：1

共 50 条

[1] Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
Lee, K.
Lee, K-H.
Kim, D-W.
Yoon, J. S.
Choi, W.
Lee, Y.
Choi, Y. J.
Lee, S.
Kim, J. W.
Ryu, H.
Koo, D-H.
Lee, Y-G.
Jeung, H-C.
Lee, M-Y.
Lee, N.
Kang, M. J.
Lee, J.
Hong, S-H.
Kang, E. J.
Park, I. H.
ANNALS OF ONCOLOGY, 2024, 35 : S253 - S254
[2] Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Kim, Tae Min
Lee, Keun-Wook
Oh, Do-Youn
Lee, Jong-Seok
Im, Seock-Ah
Kim, Dong-Wan
Han, Sae-Won
Kim, Yu Jung
Kim, Tae-You
Kim, Jee Hyun
Han, Hyesun
Kim, Woo Ho
Bang, Yung-Jue
CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 835 - 842
[3] Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
Garland, LL
Pegram, M
Song, S
Mendelson, D
Parker, KE
Martell, RE
Gordon, MS
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 229S - 229S
[4] Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
Kris, M. G.
Camidge, D. R.
Giaccone, G.
Hida, T.
Li, B. T.
O'Connell, J.
Taylor, I.
Zhang, H.
Arcila, M. E.
Goldberg, Z.
Jaenne, P. A.
ANNALS OF ONCOLOGY, 2015, 26 (07) : 1421 - 1427
[5] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Wang, Y.
Jiang, T.
Qin, Z.
Jiang, J.
Wang, Q.
Yang, S.
Rivard, C.
Gao, G.
Ng, T. L.
Tu, M. M.
Yu, H.
Ji, H.
Zhou, C.
Ren, S.
Zhang, J.
Bunn, P.
Doebele, R. C.
Camidge, D. R.
Hirsch, F. R.
ANNALS OF ONCOLOGY, 2019, 30 (03) : 447 - 455
[6] Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Yap, Timothy A.
Vidal, Laura
Adam, Jan
Stephens, Peter
Spicer, James
Shaw, Heather
Ang, Jooern
Temple, Graham
Bell, Susan
Shahidi, Mehdi
Uttenreuther-Fischer, Martina
Stopfer, Peter
Futreal, Andrew
Calvert, Hilary
de Bono, Johann S.
Plummer, Ruth
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3965 - 3972
[7] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
Zhang, Jian
Cao, Junning
Li, Jin
Zhang, Yifan
Chen, Zhiyu
Peng, Wei
Sun, Si
Zhao, Naiqing
Wang, Jiachen
Zhong, Dafang
Zhang, Xiaofang
Zhang, Jing
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
[8] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
Jian Zhang
Junning Cao
Jin Li
Yifan Zhang
Zhiyu Chen
Wei Peng
Si Sun
Naiqing Zhao
Jiachen Wang
Dafang Zhong
Xiaofang Zhang
Jing Zhang
Journal of Hematology & Oncology, 7
[9] RESULTS WITH DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN A PHASE II COHORT OF PATIENTS WITH HER2-MUTANT OR AMPLIFIED LUNG CANCERS
Kris, Mark G.
Camidge, David Ross
Giaccone, Giuseppe
Hida, Toyoaki
O'Connell, Joseph
Taylor, Ian
Zhang, Hui
Gold-Berg, Zelanna
Jaenne, Pasi A.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S609 - S610
[10] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
Opdam, F.
Heymach, J.
Barve, M.
Gibson, N.
Sadrolhefazi, B.
Serra, J.
Yamamoto, N.
Yoh, K.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422

← 1 2 3 4 5 →